Altimmune, Inc.

Next week, our Chief Executive Officer, Dr. Vipin Garg, and Chief Medical Officer, M. Scott Harris, will participate in a #firesidechat at the H.C. Wainwright 8th Annual #MASH Virtual Conference to discuss our mission to transform the therapeutic standard for #metabolicdiseases, starting with #pemvidutide, our #GLP1/#Glucagon dual receptor agonist for the treatment of #obesity and MASH. Learn more: https://bit.ly/3N64ymi    H.C. Wainwright & Co., LLC  

Today, we announced completion of patient enrollment in IMPACT, our Phase 2b biopsy-driven #clinicaltrial evaluating #pemvidutide in #MASH and provided an update on additional development and regulatory initiatives related to pemvidutide. Read the full release to learn more: https://lnkd.in/eE3Ty6DJ.

Attending the #MASH Drug Development Summit in Boston this week? Our Chief Medical Officer, M. Scott Harris, M.D., is conducting a seminar exploring the benefits of #glucagon biology on liver fat, fibrosis, body composition and more. More details here: https://bit.ly/4e69anY Hanson Wade Group

#DYK there are more than 1 billion people worldwide living with #obesity? Learn more about the unmet need in obesity and our work to address the disease: https://bit.ly/3XAP1Si 

Today, we presented data from our Phase 2, MRI-based body composition sub-study of #pemvidutide in #obesity at the European Association for the Study of Diabetes e.V. (EASD). Learn more about the data here: https://lnkd.in/eC4zzGq8. #EASD2024 

Next week, we will be presenting updated MRI-based body composition data from our 48-week Phase 2 MOMENTUM trial of #pemvidutide for #obesity at the European Association for the Study of Diabetes e.V. (EASD) in Madrid. Join us to learn more about the promising potential of pemvidutide, our #GLP1 / #Glucagon dual receptor agonist for the treatment of obesity. Learn more: https://lnkd.in/etzb2Efm. #EASD2024

Next week, our management team will be conducting 1x1 meetings at the Morgan Stanley Global Healthcare Conference in New York and the Wells Fargo Healthcare Conference in Boston. Connect with us onsite to learn more about our commitment to developing #pemvidutide, our novel therapeutic for patients with #obesity and #MASH. 

#ICYMI Our Chief Medical Officer, M. Scott Harris, M.D., sat down for an interview with Radcliffe Cardiology to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of #obesity and #MASH.  In this insightful discussion, Dr. Harris explores the clinical need for these next-gen therapeutics driving our work at Altimmune, as well as the current evidence for the use of incretins in the treatment of obesity and MASH. Watch the full interview here: https://bit.ly/3M7U2La 

At Altimmune, we strive to redefine the approach to metabolic health. #Pemvidutide, our investigational dual receptor agonist, is designed for optimal weight management and improved liver function for patients living with #obesity & #MASH. Harnessing the dual benefits of #GLP-1 and #glucagon pathways, pemvidutide has the potential to unlock new health outcomes by simultaneously tackling multiple aspects of #metabolichealth.    Learn more about our therapeutic approach in this recent Everyday Health article by Ross Wollen: https://bit.ly/4cQSpgh 

Today, we provided a corporate update and published our second quarter 2024 financial results. Learn more about our recent business highlights, including data presentations at EASL and ADA supporting #pemvidutide’s differentiated profile for the treatment of #obesity & #MASH: https://lnkd.in/evN4zAat.